|
Aug 1
|
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10
|
|
Jul 28
|
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News
|
|
Jul 28
|
Atai backs away from schizophrenia drug after trial failure
|
|
Jul 28
|
Recognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal
|
|
Jul 25
|
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
|
|
Jul 21
|
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why
|
|
Jul 1
|
A Promising Depression Drug Works. Psychedelics Are Back.
|
|
Jul 1
|
atai and Beckley Psytech’s psychedelic wins in Phase IIb depression trial
|
|
Jul 1
|
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
|
|
Jul 1
|
Atai and Beckley, set to merge, reveal study success for psychedelic drug
|
|
Jul 1
|
atai Life Sciences Announces $50 Million Private Placement Financing
|
|
Jul 1
|
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
|
|
Jun 25
|
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
|
|
Jun 19
|
Trump Trade: President said to weigh possible U.S. strike against Iran
|
|
Jun 19
|
Psychedelic advocates hopeful Trump administration will support space, STAT says
|
|
Jun 19
|
This Illegal Psychedelic Is Hailed as a ‘Revolutionary Breakthrough’
|
|
May 21
|
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies
|
|
May 21
|
Home Depot backs outlook as U.S. sales ticked up: Morning Buzz
|
|
May 20
|
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
|
|
May 14
|
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
|